Table 2.
Crohn's disease (CD) characteristics, medical treatment, endoscopic evaluation, and surgical history.
| CD characteristics | CD (n = 44) |
|---|---|
| Disease duration, years (median, IQR) | 10.0 (19.8) |
| Subclassification of patients, n (%)a | |
| Terminal ileitis (Inflamed 5-cm + normal 15-cm) | 22 (50.0%) |
| Active disease (Inflamed 5-cm + 15-cm) | 10 (22.7%) |
| Remission (Normal 5 + 15 cm) | 12 (27.3%) |
| Montreal location, n (%) | |
| Terminal ileum (L1) | 23 (52.3%) |
| Ileocolonic (L3) | 16 (36.4%) |
| Ileocolonic + Upper GI (L3 + L4) | 5 (11.4%) |
| Montreal behavior, n (%) | |
| Non-stricturing, non-penetrating (B1) | 8 (18.2%) |
| Non-stricturing, non-penetrating + perianal (B1p) | 2 (4.5%) |
| Stricturing (B2) | 15 (34.1%) |
| Stricturing + perianal (B2p) | 6 (13.6%) |
| Penetrating (B3) | 11 (25%) |
| Penetrating + perianal (B3p) | 2 (4.5%) |
| Montreal age (age at diagnosis), n (%) | |
| 16 years or younger (A1) | 12 (27.3%) |
| 17–40 years (A2) | 22 (50%) |
| Over 40 years (A3) | 10 (22.7%) |
| CD-medication, n (%)b | |
| No medical therapy for CD | 18 (40.9%) |
| Budesonide | 7 (15.9%) |
| Prednisolone | 4 (9.1%) |
| 5-ASA | 3 (6.8%) |
| Azathioprine | 6 (13.6%) |
| Methotrexate | 3 (6.8%) |
| Adalimumab | 4 (9.1%) |
| Infliximab | 7 (15.9%) |
| Vedolizumab | 1 (2.3%) |
| Treatment naïve, n (%) | 6 (13.6%) |
| Anti-TNF treatment naïve, n (%) | 23 (52.3%) |
| Rutgeerts score, n (%) | |
| i0 | 12 (27.3%) |
| i1 | 12 (27.3%) |
| i2 | 5 (11.4%) |
| i3 | 6 (13.6%) |
| i4 | 9 (20.5%) |
| Ileocecal resection | 28 (63.6%) |
a
Based on endoscopic evaluation of inflammation.
b
Co-medication: n = 8 (18.2) used two CD medications, n = 1 (2.3%) used three CD medications.